Loading…
Loading…
Video webcast now available here
Daré Bioscience, Inc. (DARE) Discusses Women's Health Portfolio and Commercial Launches During Virtual Bus Tour Transcript
Daré's proprietary formulation of topical sildenafil cream, 3.6% was well tolerated across all evaluated doses in the clinical study, with minimal systemic exposure Company continues activities necessary to advance its Sildenafil Cream toward the FDA's 505(b)(2) regulatory pathway* while in parallel launching DARE to PLAY™ Sildenafil Cream, the 503B compounded version of its proprietary sildenafil cream formulation**
President & CEO, Sabrina Martucci Johnson, discusses the Company's shift to commercial stage, upcoming revenue opportunities, Ovaprene's positive interim Phase 3 results and what could drive value over the next 12–18 months Access the segment here
National recognition comes as Daré Bioscience advances a multi-product women's health strategy across commercialization, clinical development and first-in-category innovation National recognition comes as Daré Bioscience advances a multi-product women's health strategy across commercialization, clinical development and first-in-category innovation
SAN DIEGO, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (Nasdaq: DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced that it has entered into a definitive securities purchase agreement with institutional investors for the purchase and sale of 4,379,581 shares of the Company's common stock (or pre-funded warrants to purchase shares of common stock in lieu thereof), at a price of $1.37 per share of common stock (or $1.3699 per pre-funded warrant) in a registered direct offering priced at-the-market under Nasdaq rules. Each pre-funded warrant will be exercisable upon issuance at an exercise price of $0.0001 per share and will expire when exercised in full.
Daré Bioscience, Inc. (DARE) Q2 2026 Earnings Call Transcript
Dare Bioscience, Inc. (DARE) came out with a quarterly loss of $0.2 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to a loss of $0.45 per share a year ago.